The purpose of this Phase 2 study is to determine the safety and effectiveness of investigational study drug SY-1425 in treating relapsed/refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) subjects with a certain biomarker in their blood (a blood test that may indicate the drug target is present in your type of AML or MDS). Currently, there is a great unmet need for treating these subject populations. "Investigational" means that SY-1425 has not been approved by the United States Food and Drug Administration (FDA). SY-1425 has been studied in subjects for a similar but different kind of cancer, acute promyelocytic leukemia (APL), and is available to physicians and subjects in Japan, as an approved drug called tamibarotene.
SY-1425 is a potent and selective retinoic acid receptor alpha (RAR-alpha) agonist. Retinoic acid receptors are transcription factors that are involved in your leukemia.
Detailed eligibility will be reviewed when you contact the study team.